Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation.
作者信息
Zhao Yingze, Zhao Xin, Zhang Rong, Ye Beiwei, Yuan Xiaoju, Zhang Danni, Li Lei, Tian Jinmin, Guo Yaxin, Gao George F, Liu William J
机构信息
NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing 100101, China.
出版信息
Lancet Reg Health West Pac. 2022 Mar 25;21:100440. doi: 10.1016/j.lanwpc.2022.100440. eCollection 2022 Apr.
Abstract
摘要
相似文献
1
Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation.异源BBIBP-CorV/ZF2001疫苗接种增强对SARS-CoV-2变异株的中和作用：一项初步观察。
Lancet Reg Health West Pac. 2022 Mar 25;21:100440. doi: 10.1016/j.lanwpc.2022.100440. eCollection 2022 Apr.
2
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.健康成年人中，BBIBP-CorV（国药）和 BNT162b2（辉瑞-生物科技）疫苗对 SARS-CoV-2 诱导的抗体和 T 细胞应答的比较。
Geroscience. 2021 Oct;43(5):2321-2331. doi: 10.1007/s11357-021-00471-6. Epub 2021 Oct 11.
3
Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2.血清样本对BBIBP-CorV和ZF2001疫苗针对新冠病毒501Y.V2的中和作用
Lancet Microbe. 2021 Jul;2(7):e285. doi: 10.1016/S2666-5247(21)00082-3. Epub 2021 Apr 13.
4
The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.在阿拉伯联合酋长国，一线工作者接种 BBIBP-CORV 疫苗紧急使用授权后的 COVID-19 感染发生率。
Sci Rep. 2022 Jan 11;12(1):490. doi: 10.1038/s41598-021-04244-1.
5
Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia.四种新冠病毒疫苗在塞尔维亚伏伊伏丁那≥60岁成年人中预防新冠病毒病的早期有效性
Vaccines (Basel). 2022 Mar 3;10(3):389. doi: 10.3390/vaccines10030389.
6
Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy.对灭活病毒疫苗引发的SARS-CoV-2特异性IgG反应进行系统分析，可鉴定出用于预测疫苗效力的肽段和蛋白质。
Cell Discov. 2021 Aug 17;7(1):67. doi: 10.1038/s41421-021-00309-7.
7
SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.严重急性呼吸综合征冠状病毒2型中和抗体：跨疫苗的网络荟萃分析
Vaccines (Basel). 2021 Mar 5;9(3):227. doi: 10.3390/vaccines9030227.
8
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
9
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.COVID-19 疫苗接种对癌症患者使用 PD-1 抑制剂治疗的影响：一项真实世界研究。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004157.
10
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
引用本文的文献
1
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.新型嵌合型中国mRNA（RQ3013）SARS-CoV-2疫苗异源加强接种的有效性、免疫原性和安全性：一项随机、双盲、活性对照试验。
Hum Vaccin Immunother. 2025 Dec;21(1):2502250. doi: 10.1080/21645515.2025.2502250. Epub 2025 May 16.
2
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.探索新冠病毒治疗领域：揭示关于美国食品药品监督管理局批准药物、疫苗接种目标及新兴策略的新观点
Molecules. 2024 Nov 25;29(23):5564. doi: 10.3390/molecules29235564.
3
Post-Vaccination Neutralization Responses to Omicron Sub-Variants.接种疫苗后对奥密克戎亚变体的中和反应。
Vaccines (Basel). 2022 Oct 20;10(10):1757. doi: 10.3390/vaccines10101757.
4
Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines.变异-proof 严重急性呼吸综合征冠状病毒 2、泛沙贝科病毒和泛-β-冠状病毒疫苗的研发。
J Med Virol. 2023 Jan;95(1):e28172. doi: 10.1002/jmv.28172. Epub 2022 Oct 6.
5
Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.面向新型基于纳米的SARS-CoV-2及其关注变体疫苗平台：进展、挑战与局限
J Drug Deliv Sci Technol. 2022 Oct;76:103762. doi: 10.1016/j.jddst.2022.103762. Epub 2022 Sep 8.
本文引用的文献
1
Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.延长加强针间隔时间对奥密克戎变种中和作用的影响。
N Engl J Med. 2022 Mar 3;386(9):894-896. doi: 10.1056/NEJMc2119426. Epub 2022 Jan 26.
2
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.奥密克戎变异株对疫苗加强后免疫血清的中和敏感性低于其他 SARS-CoV-2 变异株。
Emerg Microbes Infect. 2022 Dec;11(1):337-343. doi: 10.1080/22221751.2021.2022440.
3
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.科兴新冠疫苗加强免疫的免疫原性和安全性，以及两剂接种程序的免疫持久性：两项单中心、双盲、随机、安慰剂对照的 2 期临床试验的中期结果。
Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8.
4
Heavily mutated Omicron variant puts scientists on alert.高度变异的奥密克戎毒株使科学家们警觉起来。
Nature. 2021 Dec;600(7887):21. doi: 10.1038/d41586-021-03552-w.
5
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern.两剂灭活疫苗后接种重组蛋白亚单位疫苗加强针可显著增强针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其关注变异株的抗受体结合域（RBD）反应和中和效价。
Cell Res. 2022 Jan;32(1):103-106. doi: 10.1038/s41422-021-00590-x. Epub 2021 Nov 23.
6
Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants.ZF2001诱导的抗血清对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和作用。
Lancet Microbe. 2021 Oct;2(10):e494. doi: 10.1016/S2666-5247(21)00217-2. Epub 2021 Aug 20.
7
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.用异源疫苗加强免疫可有效提高灭活 SARS-CoV-2 疫苗的保护免疫应答。
Emerg Microbes Infect. 2021 Dec;10(1):1598-1608. doi: 10.1080/22221751.2021.1957401.
8
Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.截至2021年6月，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的传播性增加及其在全球的传播情况。
Euro Surveill. 2021 Jun;26(24). doi: 10.2807/1560-7917.ES.2021.26.24.2100509.
9
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
10
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.SARS-CoV-2 变体 B.1.351 和 P.1 逃避中和抗体。
Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.
Zotero 插件